InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,612.80
(
0.00%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.03
(
-1.01%
)
Bitcoin
62,163.48
(
-0.27%
)
Post# of 1721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

guay

Send PM Follow Ignore
Followers 32
Posts 3389
Boards Moderated 0
Alias Born 08/04/2009

guay

Re: None

Thursday, 12/14/2017 1:36:14 PM

Thursday, December 14, 2017 1:36:14 PM

Post# of 1721
Insys Therapeutics Inc (NASDAQ:INSY) Begins Proof-of-Concept Trial Of Epinephrine Nasal Spray Targeting Anaphylaxis
Insys Therapeutics Inc (NASDAQ:INSY) has commenced a proof-of-concept trial of two distinct formulations of epinephrine nasal spray targeting the treatment of anaphylaxis, with the registration of the first patient. This Phase I clinical study is intended to know whether intranasal dosage of epinephrine is bioequivalent to the standard process of delivering the medication, which is via intramuscular injection.
http://mmjreporter.com/insys-therapeutics-inc-nasdaqinsy-begins-proof-of-concept-trial-of-epinephrine-nasal-spray-targeting-anaphylaxis-33019.html

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up